739 related articles for article (PubMed ID: 27452466)
41. ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.
Kosari F; Ida CM; Aubry MC; Yang L; Kovtun IV; Klein JL; Li Y; Erdogan S; Tomaszek SC; Murphy SJ; Bolette LC; Kolbert CP; Yang P; Wigle DA; Vasmatzis G
Oncogene; 2014 Jul; 33(29):3776-83. PubMed ID: 24037524
[TBL] [Abstract][Full Text] [Related]
42. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.
Tlemsani C; Pongor L; Elloumi F; Girard L; Huffman KE; Roper N; Varma S; Luna A; Rajapakse VN; Sebastian R; Kohn KW; Krushkal J; Aladjem MI; Teicher BA; Meltzer PS; Reinhold WC; Minna JD; Thomas A; Pommier Y
Cell Rep; 2020 Oct; 33(3):108296. PubMed ID: 33086069
[TBL] [Abstract][Full Text] [Related]
43. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.
Jiang T; Collins BJ; Jin N; Watkins DN; Brock MV; Matsui W; Nelkin BD; Ball DW
Cancer Res; 2009 Feb; 69(3):845-54. PubMed ID: 19176379
[TBL] [Abstract][Full Text] [Related]
44. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
45. The balance between the expressions of hASH1 and HES1 differs between large cell neuroendocrine carcinoma and small cell carcinoma of the lung.
Nasgashio R; Sato Y; Matsumoto T; Kageyama T; Hattori M; Iyoda A; Satoh Y; Ryuge S; Masuda N; Jiang SX; Saegusa M
Lung Cancer; 2011 Dec; 74(3):405-10. PubMed ID: 21601304
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.
Wei J; Liu L; Guo Y; Zhang J; Wang X; Dong J; Xing P; Ying J; Yang L; Li J
Thorac Cancer; 2021 Jan; 12(1):40-47. PubMed ID: 33191657
[TBL] [Abstract][Full Text] [Related]
47. Recent advances in histogenesis research of lung neuroendocrine cancers: Evidence obtained from functional analyses of primitive neural/neuroendocrine cell-specific transcription factors.
Yazawa T
Pathol Int; 2015 Jun; 65(6):277-85. PubMed ID: 25708144
[TBL] [Abstract][Full Text] [Related]
48. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.
Mollaoglu G; Guthrie MR; Böhm S; Brägelmann J; Can I; Ballieu PM; Marx A; George J; Heinen C; Chalishazar MD; Cheng H; Ireland AS; Denning KE; Mukhopadhyay A; Vahrenkamp JM; Berrett KC; Mosbruger TL; Wang J; Kohan JL; Salama ME; Witt BL; Peifer M; Thomas RK; Gertz J; Johnson JE; Gazdar AF; Wechsler-Reya RJ; Sos ML; Oliver TG
Cancer Cell; 2017 Feb; 31(2):270-285. PubMed ID: 28089889
[TBL] [Abstract][Full Text] [Related]
49. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).
Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY
World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975
[TBL] [Abstract][Full Text] [Related]
50. Dynamic transition of molecular subtypes in relapsed small cell lung cancer treated with multimodal therapy: A case report.
Yasuda K; Haruki T; Miyamoto T; Oshima Y; Matsui S; Kubouchi Y; Nakamura H
Thorac Cancer; 2023 Jul; 14(20):2001-2004. PubMed ID: 37253435
[TBL] [Abstract][Full Text] [Related]
51. The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Oser MG; Sabet AH; Gao W; Chakraborty AA; Schinzel AC; Jennings RB; Fonseca R; Bonal DM; Booker MA; Flaifel A; Novak JS; Christensen CL; Zhang H; Herbert ZT; Tolstorukov MY; Buss EJ; Wong KK; Bronson RT; Nguyen QD; Signoretti S; Kaelin WG
Genes Dev; 2019 Dec; 33(23-24):1718-1738. PubMed ID: 31727771
[TBL] [Abstract][Full Text] [Related]
52. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
[TBL] [Abstract][Full Text] [Related]
53. Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer.
Finlay JB; Ireland AS; Hawgood SB; Reyes T; Ko T; Olsen RR; Abi Hachem R; Jang DW; Bell D; Chan JM; Goldstein BJ; Oliver TG
Cancer Cell; 2024 Jun; 42(6):1086-1105.e13. PubMed ID: 38788720
[TBL] [Abstract][Full Text] [Related]
54. Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer.
Fushimi A; Morimoto Y; Ishikawa S; Yamashita N; Bhattacharya A; Daimon T; Rajabi H; Jin C; Hagiwara M; Yasumizu Y; Luan Z; Suo W; Wong KK; Withers H; Liu S; Long MD; Kufe D
Mol Cancer Res; 2022 Sep; 20(9):1379-1390. PubMed ID: 35612556
[TBL] [Abstract][Full Text] [Related]
55. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR
Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888
[TBL] [Abstract][Full Text] [Related]
56. Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers.
Huang F; Ni M; Chalishazar MD; Huffman KE; Kim J; Cai L; Shi X; Cai F; Zacharias LG; Ireland AS; Li K; Gu W; Kaushik AK; Liu X; Gazdar AF; Oliver TG; Minna JD; Hu Z; DeBerardinis RJ
Cell Metab; 2018 Sep; 28(3):369-382.e5. PubMed ID: 30043754
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.
Tsuboyama N; Wang R; Szczepanski AP; Chen H; Zhao Z; Shi L; Wang L
Oncogene; 2022 Apr; 41(15):2152-2162. PubMed ID: 35194152
[TBL] [Abstract][Full Text] [Related]
58. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
[TBL] [Abstract][Full Text] [Related]
59. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
[TBL] [Abstract][Full Text] [Related]
60. Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors.
Westerman BA; Breuer RH; Poutsma A; Chhatta A; Noorduyn LA; Koolen MG; Postmus PE; Blankenstein MA; Oudejans CB
Int J Biol Markers; 2007; 22(2):114-23. PubMed ID: 17549667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
